Large number of U.S. COVID deaths could be prevented if patients would take Pfizer's Paxlovid, White House coordinator warns

United States News News

Large number of U.S. COVID deaths could be prevented if patients would take Pfizer's Paxlovid, White House coordinator warns
United States Latest News,United States Headlines
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 31 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 97%

The average daily COVID death count could be reduced to about 50 a day from 400 currently – if every patient aged 50 either took Paxlovid or used monoclonal antibodies, White House COVID coordinator Dr. Ashish Jha said.

A large number of U.S. COVID deaths could be prevented if patients would take Paxlovid, the antiviral developed by Pfizer PFE, -1.47% that helps reduce the risk of hospitalization and death, according to White House COVID coordinator Dr. Ashish Jha.

The issue seems to be a combination of worry about certain issues that Paxlovid can cause, including a strange metallic taste and the potential for “rebound COVID,” where patients quickly become reinfected after the five-day course of pills has been completed. That happened to both President Joe Biden and first lady Jill Biden recently.

“I think almost everybody benefits from Paxlovid,” Jha said. “For some people, the benefit is tiny. For others, the benefit is massive.” The daily average for hospitalizations was down 11% at 27,021, while the daily average for deaths is down 8% to 391.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

MarketWatch /  🏆 3. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

COVID rebound after Pfizer treatment likely due to robust immune response, study findsCOVID rebound after Pfizer treatment likely due to robust immune response, study findsA rebound of COVID-19 symptoms in some patients after taking Pfizer's antiviral Paxlovid may be related to a robust immune response rather than a weak one, U.S. government researchers reported on Thursday. They concluded that taking a longer course of the drug - beyond the recommended five days - was not required to reduce the risk of a recurrence of symptoms as some have suggested, based on an intensive investigation of rebound in eight patients at the National Institutes of Health's Clinical Center. All patients in the study had developed robust immune responses, but researchers found higher levels of antibodies in the patients who experienced a rebound.
Read more »

CDC ending daily reporting of COVID case and death dataCDC ending daily reporting of COVID case and death data'To allow for additional reporting flexibility, reduce the reporting burden on states and jurisdictions, and maximize surveillance resources, CDC is moving to a weekly reporting cadence,' the agency wrote.
Read more »

CDC ends daily reporting of COVID case and death data, in shift to weekly updatesCDC ends daily reporting of COVID case and death data, in shift to weekly updatesThe shift comes as federal health officials are bracing for a renewed wave of COVID-19 infections this fall and winter.
Read more »

Covid-19 boosters could prevent about 90,000 US deaths this winter, but only if more people get them, analysis suggests | CNNCovid-19 boosters could prevent about 90,000 US deaths this winter, but only if more people get them, analysis suggests | CNNCovid-19 vaccinations could save thousands of lives and billions of dollars this winter.
Read more »

Amid end to COVID help, homelessness surging in many citiesAmid end to COVID help, homelessness surging in many citiesHomelessness is expected to be up when the federal government releases results from an annual count in coming months, the first full tally since the coronavirus pandemic began
Read more »



Render Time: 2025-03-13 12:55:04